Fig. 1
From: Circulating tumor cells capture disease evolution in advanced prostate cancer
Clinical timecourse of disease. a Hematoxylin-Eosin stain (top) and immunohistochemical analysis of PSA protein (bottom) of treatment-naive bone biopsy diagnosing metastatic prostate cancer. b Clinical timecourse indicating PSA levels, timing of biopsies, timing of the single CTC collection ~3 weeks after CRPC biopsy, which was divided into three pools, and timing of therapies. CAB combined androgen blockade, abi abiraterone, doc docetaxel, RT palliative radiation therapy, CE carboplatin and etoposide. c CT image of liver metastasis that underwent biopsy (white arrowhead). d Fraction of PCR targets that were amplified from each whole genome amplification product